×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Neuronetics's NeuroStar wins FDA clearance for adolescents with depression
Medical Device Network
Neuronetics's NeuroStar wins FDA clearance for adolescents with depression. Teenagers aged 15-21 years in the US are eligible to use the...
1 month ago
Neuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call Transcript
Yahoo Finance
Neuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call Transcript May 7, 2024 Neuronetics, Inc. beats earnings expectations.
1 week ago
Neuronetics stock upgraded by William Blair on adolescent treatment potential
Investing.com
On Tuesday, Neuronetics (NASDAQ:STIM) stock, received an upgrade from Market Perform to Outperform by an analyst at William Blair.
5 days ago
Neuronetics Nabs FDA Clearance for NeuroStar Treatment in Adolescents
Medical Device and Diagnostic industry
It's fourth FDA-cleared indication for the device, NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment for the 15...
1 month ago
Neuronetics' magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depression
Fierce Biotech
The FDA based its decision in part on real-world data collected by Neuronetics through its TrakStar registry platform. According to the company,...
1 month ago
FDA clears Neuronetics' neurostim for adolescents with depression
MassDevice
Neuronetics announced today that it received FDA clearance for the use of its NeuroStar therapy for adolescent patients.
1 month ago
Neuronetics: Q1 Earnings Snapshot
Milford Mirror
MALVERN, Pa. (AP) — MALVERN, Pa. (AP) — Neuronetics Inc. (STIM) on Tuesday reported a loss of $7.9 million in its first quarter.
2 weeks ago
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Simply Wall Street
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) had a terrible week, as shares crashed 28% to US$2.55 in the week...
1 week ago
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
MarketWatch
By Sabela Ojea Shares of Neuronetics on Monday climbed after the company said the U.S. Food and Drug Administration cleared its NeuroStar...
1 month ago
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
Morningstar
Shares of Neuronetics on Monday climbed after the company said the U.S. Food and Drug Administration cleared its NeuroStar Advanced Therapy as...
1 month ago